22:52 , Nov 2, 2018 |  BC Extra  |  Politics & Policy

CMS rule cuts reimbursement for new Part B drugs

Under a new rule, CMS will reimburse newly launched physician-administered drugs covered under Medicare Part B at the wholesale acquisition cost (WAC) plus 3%, down from WAC plus 6%, effective Jan. 1, 2019. Under the...
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
18:28 , Jun 29, 2018 |  BC Week In Review  |  Financial News

C-Bridge leads Nuance's series B

Nuance Biotech (Shanghai) Co. Ltd. (Shanghai, China) raised $20 million in a series B round led by C-Bridge Capital. Nuance is eligible to receive an additional $15 million from C-Bridge for acquiring new products. Nuance...
21:19 , Jun 28, 2018 |  BC Extra  |  Financial News

C-Bridge leads Nuance's series B

Nuance Biotech (Shanghai) Co. Ltd. (Shanghai, China) raised $20 million in a series B round led by C-Bridge Capital. Nuance is eligible to receive an additional $15 million from C-Bridge for acquiring new products. Nuance...
17:07 , Jun 26, 2018 |  BC Week In Review  |  Company News

Nuance gains Chinese rights to Pacira's Exparel

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) granted Nuance Biotech Co. Ltd. (Shanghai, China) exclusive rights to develop and commercialize Exparel bupivacaine in China. Pacira is to receive $3 million up front and is eligible for $55 million...
18:27 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Heron's pain candidate meets in Phase IIb ahead of NDA

Heron Therapeutics Inc. (NASDAQ:HRTX) reported that HTX-011 met the primary endpoint in a pair of Phase IIb trials to treat postoperative pain. Heron intends to submit an NDA to FDA next half for the candidate....
18:57 , Jun 21, 2018 |  BC Extra  |  Clinical News

Heron flying on Phase IIb pain data ahead of NDA

Heron Therapeutics Inc. (NASDAQ:HRTX) added $9.25 (30%) to $39.95 on Thursday after reporting that HTX-011 met the primary endpoint in a pair of Phase IIb trials to treat postoperative pain. The stock move added more...
20:34 , May 14, 2018 |  BC Week In Review  |  Clinical News

Concentric reports Phase Ib data for non-opioid postsurgical pain candidate

Concentric Analgesics Inc. (San Francisco, Calif.) reported top-line data from a Phase Ib trial to treat postsurgical pain following a bunionectomy showing that the highest dose of a single intraoperative injection of CA-008 led to...
13:50 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

FDA approves Pacira's sNDA for Exparel

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) said FDA approved an sNDA for Exparel bupivacaine as a nerve block administered via interscalene brachial plexus to produce regional analgesia in patients undergoing upper extremity surgeries. In February, an FDA...
22:30 , Apr 6, 2018 |  BC Extra  |  Company News

Pacira's Exparel gets label expansion as nerve block

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) said late Friday that FDA approved an sNDA for Exparel bupivacaine as a nerve block administered via interscalene brachial plexus to produce regional analgesia in patients undergoing upper extremity surgeries. In...